Core Viewpoint - PROCEPT BioRobotics Corporation (PRCT) has received an upgrade to a Zacks Rank 1 (Strong Buy), indicating a positive outlook based on rising earnings estimates, which significantly influence stock prices [1][4][6]. Earnings Estimates and Revisions - The Zacks rating system is centered around the changing earnings picture, tracking the Zacks Consensus Estimate for EPS from sell-side analysts for the current and following years [2]. - Rising earnings estimates for PROCEPT BioRobotics indicate an improvement in the company's underlying business, which is expected to drive stock price appreciation [6][9]. - The company is projected to earn -$1.75 per share for the fiscal year ending December 2024, reflecting a year-over-year change of 21.9% [9]. Zacks Rating System - The Zacks Rank stock-rating system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988 [8]. - The system maintains a balanced distribution of 'buy' and 'sell' ratings, ensuring that only the top 5% of stocks receive a 'Strong Buy' rating, indicating superior earnings estimate revisions [10][11]. Market Implications - The upgrade of PROCEPT BioRobotics to a Zacks Rank 1 positions it among the top 5% of Zacks-covered stocks, suggesting potential for market-beating returns in the near term [11]. - The correlation between earnings estimate revisions and near-term stock movements highlights the importance of tracking these revisions for investment decisions [7].

SAN JOSE, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming 36th Annual Piper Sandler Healthcare Conference in New York City. Management is scheduled to present on Wednesday, December 4 at 8:30 a.m. Eastern Time. A live webcast of each event, as well as an archived recording, will ...

Core Insights - PROCEPT BioRobotics Corporation (NASDAQ: PRCT) has seen a stock increase of 20% following recent fundamental updates, now trading at approximately 16 times forward sales and 20 times book value as investors reassess the value of its equity [1] Group 1 - The stock's performance reflects a positive reappraisal by investors regarding the company's equity value [1] - The current trading multiples indicate a strong market interest and potential growth outlook for PROCEPT BioRobotics [1]

Company Overview - PROCEPT BioRobotics Corporation (PRCT) currently holds a Momentum Style Score of A, indicating strong momentum potential [3] - The company has a Zacks Rank of 2 (Buy), suggesting favorable market performance [4] Price Performance - PRCT shares have increased by 34.2% over the past week, while the Zacks Medical - Instruments industry remained flat during the same period [6] - Over the past month, PRCT's price change is 32.49%, significantly outperforming the industry's 2.19% [6] - In the last quarter, PRCT shares rose by 52.15%, and over the past year, they gained 198.93%, compared to the S&P 500's increases of 13.52% and 37.4%, respectively [7] Trading Volume - The average 20-day trading volume for PRCT is 1,193,537 shares, which serves as a bullish indicator when combined with rising stock prices [8] Earnings Outlook - In the past two months, 6 earnings estimates for PRCT have been revised upwards, while none have been revised downwards, leading to an increase in the consensus estimate from -$1.88 to -$1.74 [10] - For the next fiscal year, 5 estimates have moved upwards, with 1 downward revision during the same period [10]

Group 1 - PROCEPT BioRobotics Corporation announced a public offering of 1,923,076 shares of common stock at a price of $91.00 per share, aiming for gross proceeds of approximately $175 million [1] - A selling stockholder has granted underwriters a 30-day option to purchase an additional 288,461 shares at the public offering price [1] - The offering is expected to close on or about October 31, 2024, subject to customary closing conditions [1] Group 2 - BofA Securities, Piper Sandler, and Morgan Stanley are acting as joint book-running managers for the offering [2] - The securities are being offered under an effective shelf registration statement filed with the SEC on August 1, 2023 [2] Group 3 - PROCEPT BioRobotics focuses on developing transformative solutions in urology, including the AQUABEAM® and HYDROS™ Robotic Systems [5] - The HYDROS Robotic System is noted as the only AI-powered robotic technology delivering Aquablation therapy, which is designed for effective treatment of lower urinary tract symptoms due to BPH [5] - BPH affects approximately 40 million men in the United States, highlighting the market potential for PROCEPT BioRobotics' solutions [5]

PROCEPT BioRobotics Corporation (PRCT) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices. A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and followin ...

SAN JOSE, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ: PRCT) ("PROCEPT BioRobotics" or the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced the commencement of an underwritten public offering of $175,000,000 of shares of its common stock. A selling stockholder also expects to grant the underwriters a 30-day option to purchase up to an additional $26,250,000 of shares of the Comp ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40797 PROCEPT BioRobotics Corporation (Exact name of registrant as specified in its charter) Delaware 26-0199180 (State or o ...

PROCEPT BioRobotics PRCT stock is trading on Monday after the company released better-than-expected third-quarter earnings. The company reported EPS loss of $(0.40), down from $(0.51) a year ago, beating the consensus loss of $(0.49). The surgical robotics company reported third-quarter sales of $58.4 million, up 66.3% year-over-year, beating the consensus of $53.18 million. The increase was primarily driven by increased system sales, higher average selling prices, and increased handpiece and other consumab ...

PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Q3 2024 Earnings Conference Call October 28, 2024 8:00 AM ET Company Participants Matt Bacso - Vice President, Investor Relations Reza Zadno - Chief Executive Officer Sham Shiblaq - Chief Commercial Officer Kevin Waters - Chief Financial Officer Conference Call Participants Craig Bijou - Bank of America Securities Brandon Vasquez - William Blair Richard Newitter - Truist Josh Jennings - TD Cowen Chris Pasquale - Nephron Research Ryan Zimmerman - BTIG Brett Gasaw ...